In Silico and in vitro Evaluation of a Recombinant Fusion Peptide as a Novel Candidate Vaccine for EGFR-positive Tumors

Abstract

The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK). EGFR over expressed in different cancers

A novel recombinant anti‐epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model

“…The recombinant EM‐L2 peptide was expressed and purified using a method reported by Asadi‐Ghalehni et al . . One microgram of purified recombinant EM‐L2 peptide in 100 μL Na 2 CO 3 /NaHCO 3 buffer was coated into each well of an ELISA plate and incubated at 37°C for 4 hr.…”

“…Such methods can efficiently stimulate patients’ immune systems to eliminate cancer and inhibit its spread . Previously, we mapped ICR‐62 (an EGFR mAb) and reported an EGFR mimotope, short peptide molecules mimicking epitope structure, and proved its anti‐tumour activity . To design a vaccine candidate capable of inducing a significant humoral immune response, we decided to construct a novel recombinant peptide vaccine, composed of L2 domain of EGFR and the EGFR mimotope (EM‐L2).…”

“…To design a vaccine candidate capable of inducing a significant humoral immune response, we decided to construct a novel recombinant peptide vaccine, composed of L2 domain of EGFR and the EGFR mimotope (EM‐L2). Since bioinformatics tools are currently employed in various aspects of biological studies such as investigating the mechanism and structure of various proteins and vaccine design , we have used these tools to design a EM‐L2 recombinant peptide vaccine . Herein, using ectopic Lewis lung carcinoma animal model, we evaluated prophylactic and therapeutic potentials of this new recombinant peptide vaccine.…”